Analyst Reco. KALA BIO, Inc. London S.E.

Equities

0JQ2

US4831192020

Market Closed - London S.E. Other stock markets 09:08:57 21/04/2023 pm IST			5-day change	1st Jan Change
15.38 ^USD	+4,247.09%		+126.68%	+120.22%

28/06	KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP	CI
27/06	Top Midday Gainers	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating	17/05	MT
HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	02/04	MT
HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $22 From $24, Maintains Buy Rating	17/11	MT
Wedbush Lowers Kala Pharmaceuticals' PT to $22 From $39, Moves US Launch Estimate for Lead Asset KPI-012; Maintains Outperform Rating	14/11	MT
Wedbush Cuts Kala Pharmaceuticals' Price Target to $39 From $42, Maintains Outperform Rating	05/23/05	MT
HC Wainwright & Co. Adjusts Price Target on Kala Pharmaceuticals to $22 From $20, Keeps Buy Rating	12/23/12	MT
HC Wainwright Adjusts Price Target on Kala Pharmaceuticals to $20 From $12, Keeps Buy Rating	06/23/06	MT
Wedbush Lowers Kala Pharmaceuticals' Price Target to $42 From $47 Due to Increased Share Count, Keeps Outperform Rating	06/23/06	MT
Wedbush Raises Kala Pharmaceuticals' PT to $47 From $3 on Reduced Share Count to Account for Reverse Stock Split; Keeps Outperform Rating	09/22/09	MT
HC Wainwright Adjusts Kala Pharmaceuticals' Price Target to $2.50 From $4, Keeps Buy Rating	15/22/15	MT
Oppenheimer Adjusts Kala Pharmaceuticals' Price Target to $2 From $5, Maintains Outperform Rating	24/22/24	MT
HC Wainwright Adjusts Kala Pharmaceuticals' Price Target to $4 From $5, Keeps Buy Rating	24/22/24	MT
HC Wainwright Trims Kala Pharmaceuticals' Price Target to $5 From $6, Maintains Buy Rating	17/22/17	MT
HC Wainwright Adjusts Price Target on Kala Pharmaceuticals to $5 From $6, Reiterates Buy Rating	17/22/17	MT
Wedbush Adjusts Kala Pharmaceuticals' Price Target to $3 From $6, Keeps Outperform Rating	17/22/17	MT
Northland Capital Adjusts Kala Pharmaceuticals' Price Target to $4 from $6, Keeps Outperform Rating	30/22/30	MT
Oppenheimer Adjusts Kala Pharmaceuticals Price Target to $5 From $8, Maintains Outperform Rating	30/22/30	MT
HC Wainwright Adjusts Kala Pharmaceuticals' Price Target to $6 from $9, Keeps Buy Rating	30/22/30	MT
JPMorgan Downgrades Kala Pharmaceuticals to Underweight From Neutral; Price Target is $1.50	30/22/30	MT
Wedbush Lowers Kala Pharmaceuticals' Price Target to $6 From $16 on 'Persisting Issues' Affecting Inveltys, Eysuvis Launches; Outperform Rating Kept	15/21/15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. KALA BIO, Inc. London S.E.

Equities

0JQ2

US4831192020

Analyst Reco.

Filters